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Abstract
The protozoan parasite, Trypanosoma cruzi, is the causative agent of Chagas disease (ChD), or
American trypanosomiasis, which affects 6-8 million people in Latin America. It is estimated
that 2-3 million people will develop severe lifelong cardiac and/or digestive disorders. ChD has
become a life threat not only to endemic regions but most recently also to nonendemic regions,
including the United States, owing to extensive worldwide migration in recent years. The lack of
a vaccine and the limited efficacy of the two drug treatments available make it urgent to develop
novel therapies to treat such a threatening disease. UDP-Galactopyranose mutase (UGM) is a
flavoenzyme that catalyzes the conversion of UDP-galactopyranose to UDP-galactofuranose, the
precursor of galactofuranose (Galf). In T. cruzi, Galf is found on O-linked oligosaccharides of
glycosylphosphatidylinositol

(GPI)-anchored

mucin

glycoproteins

and

glycoinositolphospholipids (GIPLs), which are highly abundant surface molecules involved in
parasite virulence (mucins) and attachment to the insect-vector (GIPLs). Galf is found in several
pathogenic organisms but not in humans, thus making the elucidation of its biosynthetic pathway
attractive for the development of more effective drugs or vaccines for ChD. The limited genetic
tools available to study T. cruzi remains a limiting factor to generate deletion mutants. Here, we
propose employing the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9
(CRISPR-associated gene 9) system to knockout T. cruzi UGM and identify its essentiality in
parasite survival and/or virulence. To this end, we employed the Cas9/sgRNA/pTREX-n
attached to a green fluorescent reporter. A donor DNA containing the tag sequence and a marker
for antibiotic resistance (blasticidin) were employed to repair the double strand break by
homologous recombination. After 7 weeks of transfection, we demonstrated that disruption of
UGM is not essential for the survival of T. cruzi. These experiments will further our

vi

understanding about T. cruzi UGM, thus, providing potential targets that can be considered in the
future development of new drugs and/or vaccines for ChD.
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Chapter I: Introduction

I.1 Chagas disease and its causative agent, Trypanosoma cruzi

Chagas disease (ChD), also known as American trypanosomiasis, is a neglected tropical
infectious disease caused by the hemoflagellate protozoan parasite, Trypanosoma cruzi (T.
cruzi). ChD was first discovered in 1909 by the Brazilian physician Carlos Chagas. Currently,
the disease affects about 6 to 8 million people in Latin America (1,2). Originally confined to the
poorest and rural areas of South and Central America, ChD has crossed frontiers and became an
important health problem to nonendemic countries in Europe, the Western Pacific Area,
Australia, Japan, and the U.S. (Fig. 1). A recent increase in migratory movements from people
residing in endemic countries has spread and alarm about the globalization of ChD (1). Only in
the United States, an estimated 300,000 people are thought to be chronically infected. On the
other hand, Spain is the country having the second number of reported cases of infected
immigrants (3-6).
T. cruzi is a kinetoplastid protozoan that is normally transmitted to humans and other
mammal reservoirs through the infected feces of a blood-sucking triatomine insects, popularly
known as “kissing bugs”, which are the disease vectors. Infection with T. cruzi begins when an
infected triatomine insect takes a blood meal and defecates close to the wounded area (Fig. 2).
Metacyclic trypomastigotes, which are infective forms of the parasite, are present in the insect’s
excrements and will enter the body through the bite wound or exposed oral or ocular mucosa.
Inside the mammalian host, the parasites will invade different types of nucleated cells, mainly by
a lysosome-mediated mechanism (7). The trypomastigotes will then escape the parasitophorous
vacuole to the cytoplasm and differentiate into rounded, non-flagellated amastigote forms, which
1

replicate by binary fission. The amastigotes will differentiate into trypomastigotes, which upon
host-cell plasma membrane rupture will be released in the extracellular milieu, eventually
reaching the bloodstream. The circulating trypomastigotes will travel through the bloodstream
invading different tissues and organs, starting new replicative cycles in a variety of nucleated
cells (7,8). Bloodstream trypomastigotes will be available to infect triatomine vectors when they
blood feed from the mammalian host. Inside the kissing bug, ingested trypomastigotes will
transform into the non-infective forms of the parasite, epimastigotes, inside the vector’s midgut.
Then, the epimastigotes will travel to the hindgut where they will transform into infective
metacyclic trypomastigotes, therefore completing the life cycle of the parasite (9). Other routes
of transmission include blood transfusion, organ transplantation, congenital (mother to child at
birth), and laboratory accidents (10). In addition, increasing number of outbreaks of oral
transmission through contaminated foods and juices have been reported (11). If the infection is
left untreated, the parasite remains for the rest of the host’s life span.

2

Figure 1. Estimated number of immigrants infected with Trypanosoma cruzi residing in
nonendemic countries. Figure taken from (1).
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Figure 2. Life cycle of Trypanosoma cruzi. Infection with T. cruzi begins when a triatomine
“kissing bug” takes a blood meal, and releases metacyclic trypomastigotes in its feces. The
trypomastigotes will be introduced inside the host through the insect bite wound or mucosal
membranes. Upon entry in the body, the parasites will invade nucleated cells and differentiate
into non-flagellated amastigotes. The amastigotes will replicate by binary fission and, after a few
replication cycles, differentiate into bloodstream trypomastigotes. These forms will rupture the
cell membrane and escape to the extracellular milieu to infect surrounding cells or to reach the
bloodstream, and therefrom invade other cells and tissues. A new triatomine will take a blood
meal and ingest bloodstream trypomastigotes from an infected mammalian host. Shortly after,
they will differentiate into epimastigotes, which will replicate in the midgut of the insect vector.
Upon nutritional stress, epimastigotes detach from the midgut epithelium, travel to the hindgut,
and differentiate into highly infective metacyclic trypomastigotes, which will be then excreted
with the feces (3,12). Figure taken from (3).
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There are three clinical phases or stages of ChD: acute, indeterminate, and chronic. The
acute phase usually lasts from 4 to 8 weeks and is characterized by high parasitemia. In most of
the patients, the infection is usually asymptomatic or present non-specific symptoms (e.g.,
general malaise, fever, fatigue, head and body aches, nausea, and vomiting). However, if the
infection occurs through vector-borne transmission, the site of parasite inoculation is
characterized by a skin lesion known as “Chagoma”. In other cases, inoculation occurs via the
conjunctiva, which leads to periorbital swelling, palpebral edema, and conjunctivitis, which are
collectively known as Romaña’s sign (1,12). However, when symptoms are present, they can
include fever, headache, rashes, enlarged lymph nodes, muscle pain, difficulty in breathing, and
swelling. Severe acute phase, which occur in less than 1% patients, includes cases of acute
myocarditis, pericardial infusion, and meningoencephalitis, which can be life-threatening if left
untreated (3). Patients with low or undetectable parasitemia and no evident disease symptoms are
considered to present the “indeterminate” form of the disease, which can last many years in most
patients. However, approximately 30 to 40% of those asymptomatic carriers will manifest the
chronic phase of the disease, which is characterized by three major clinical manifestations:
cardiac, digestive, and/or cardiodigestive (1,13). During the chronic phase, ~30% of patients
suffer from cardiac disorders, ranging from heart’s conduction-system abnormalities, arrhythmia,
heart-muscle disorders, ventricular dysfunction, and dilated cardiomyopathy, the latest being the
most serious and threatening form of ChD (10,14). A considerable number of patients in the
chronic phase are under great risk of cardiac stroke, particularly anterior circulation infarction,
which is one of the leading causes of death in Latin America (10,14-16). The gastrointestinal
form of ChD affects the esophagus, colon, or both, resulting in megaesophagus or megacolon.
Approximately 10 to 15% of chronically-ill patients will suffer from either of these medical
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afflictions. Megaesophagus causes epigastric pain, regurgitation, and malnutrition in severe
cases, whereas megacolon can affect the rectum or descending colon, provoking prolonged
obstipation, abdominal distension, and large bowel obstruction (1).
As of today, benznidazole and nifurtimox are the only two medicines to show sufficient
efficacy in the treatment of ChD. Recently, in August 2017, access to benznidazole was
approved for the first time in the U.S.A., for children between 2 and 12 years, therefore moving a
step forward in the treatment and recognition of tropical infectious diseases outside of endemic
countries (17). If the infection is treated during the onset of the acute phase, success rate is
almost 100%, and ~60-80% in children and adults with recent chronic infections. However, the
chemotherapy efficacy in adults with chronic, long-established infections is significantly lower
and variable (18,19). Recent clinical trials using successive quantitative PCR determinations to
evaluate parasitemia, indicate that benznidazole eliminates the parasite from circulation in ~80%
of patients (20,21). Similar therapeutic success has been described for nifurtimox (19). However,
chemotherapy with benznidazole or nifurtimox show serious adverse effects, such as digestive
intolerance, anorexia, weight loss, vomiting, headache, myalgia, among others in 10-27% of
patients (3,19), therefore, outweighing the benefits from the risks in the efficacy of the treatment.
In addition to the serious side effects, efficacy of these drugs usually requires a 60- and 90-day
treatment regimen for benznidazole and nifurtimox, respectively, and access to these drugs are
limited even in endemic countries, posing a difficult burden in the eradication of ChD. Currently,
there’s no clinical vaccine against ChD or any other improved therapies, despite many
experimental efforts in the last several years (22-24). Consequently, it is crucial to discover new
molecular targets in T. cruzi and develop new therapeutic approaches for ChD.
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I.2 Glycoconjugates on the surface of T. cruzi

The surface glycocalyx of T. cruzi is composed of glycosylphosphatidylinositol (GPI)anchored glycoconjugates, which are highly associated to the virulence, infectivity and survival
of the parasite. These glycoconjugates include the mucin-like glycoproteins, trans-sialidases
(TS), mucin-associated surface proteins (MASPs), and glycoinositolphospholipids (GIPLs) (Fig.
3A). The structure of these GPI anchors in T. cruzi consists of a glycan core containing four
mannoses linked to a glucosamine, which is attached to a phosphatidylinositol (PI) moiety that
contains one or two lipid tails. The C-terminus of the protein is linked to the glycan core via an
ethanolaminephosphate (25-28) (Fig. 3B). The most abundant surface glycoconjugates in all
morphological stages of T. cruzi are the mucin-like glycoproteins (or mucins) and GIPLS, which
they coat approximately 60-80% of the parasite’s surface (27-30). A study conducted by PereiraChioccola et al. (2000) demonstrated that GIPLs are more abundant in the epimastigote form of
T. cruzi, whereas mucins outnumbered GIPLs in the trypomastigote form of the parasite (31).
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Figure 3. Surface glycocalyx of Trypanosoma cruzi. (A) The surface coat of T. cruzi is covered
by glycoproteins of three major families (i.e., mucin, TS, and MASP) and glycolipids (GIPLs),
attached to the plasma membrane via a GPI-anchor (27,29). (B) Schematic representation of a
typical
T.
cruzi
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Almeida (unpublished).
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I.3 UDP-Galactopyranose mutase (UGM) and its role in the biosynthesis of betagalactofuranose (bGalf) in T. cruzi

T. cruzi possesses a dynamic life cycle, where the different sugar moieties on the cell surface
are constantly changing, therefore exerting a potential role in the infectivity, cell recognition and
adhesion during disease propagation, and resistance of the host’s immune defense (32). Out of
these molecules, there is a unique sugar present on the T. cruzi cell surface, known as bgalactofuranose (b-Galf) (30,32,33). b-Galf is a five-member ring form of galactose (Figure 4A)
and it has been found on the cell surface of many other human pathogens such as Mycobacterium
tuberculosis, Escherichia coli, Salmonella typhimurium, and Klebsiella pneumoniae (34). In
addition, b-Galf is also present in other protozoan (trypanosomatid) parasites, such as
Leishmania major, L. mexicana, Leptomonas samueli, Endotrypanum schaudinni, and
Trypanosoma dionisii (33,35,36). In T. cruzi, b-Galf residues are found in O-linked
oligosaccharides of glycosylphosphatidylinositol (GPI)-anchored mucins and GIPLs, playing an
important role in parasite host-interactions and pathogenesis (30,32) (Figure 5). However, thus
far, b-Galf has only been observed in O-glycans of GPI-mucins purified from strains belonging
to genotype or discrete typing unit (DTU) TcI (G,

Colombiana, and Dm28c) and TcVI

(Tulahuen) (37,38), although the parasite has been classified into distinct six genotypes (TcI-VI)
(39) (Figure 5A). Interestingly, b-Galf has not been found in GPI-mucin-derived O-glycans from
CL-Brener strain, which like Tulahuen strain also belongs to DTU TcVI. On the other hand, bGalf residues seem to be more ubiquitous in GIPLs, being found in every parasite genotype,
strain, or clone so far analyzed (30,32,33,40) (Figure 5B). Different studies have shown the
antigenicity of T. cruzi GIPLs in human and rabbit, mainly caused by the terminal b-Galf
residues (30,41,42). Moreover, it was shown that GIPLs are involved in the in attachment of the
9

parasites in the luminal midgut surface of the vector Rhodnius prolixus (43). The administration
of 0.5 µM Dm28c epimastigote-derived GIPLs to infected blood meal inhibited ~90% parasite
attachment to the vector’s midgut epithelium, demonstrating the importance of b-Galf in the
binding of T. cruzi epimastigotes to the insect’s midgut (43).
The key enzyme responsible in the biosynthesis of b-Galf is uridine diphosphate
(UDP)-galactopyranose mutase (UGM), a flavoenzyme that catalyzes the conversion of UDPgalactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf), the nucleotide-sugar donor of
Galf (Fig. 4B) (44). This enzyme was discovered for the first time in the E. coli K-12 strain in
1996, and later on in other pathogens such as M. tuberculosis, Aspergillus fumigatus, and L.
major, and it was found that it was the only source to produce b-Galf, and more importantly, that
this sugar is not present in mammals (42,45,46).

Figure 4. (A) b-Galf structure. (B) Conversion of UDP-Galp to UDP-Galf catalyzed by UGM.
(C) Chemical structures of oxidized and reduced forms of the flavin cofactor. Figure A was
taken from ChemSpider (http://www.chemspider.com/Chemical-Structure.9194630.html);
figures B and C were adapted from Oppenheimer et al., 2012 and Tanner et al., 2014 (44,47).
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Figure 5. Schematic representation of β-galactofuranose (β-Galf) expressed in GIPLS and
GPI-mucin O-glycans of T. cruzi. (A) Proposed structure of a GIPL with one β-Galf residue in
T. cruzi strains CL, G, G-645, and Y. (B) Proposed structure of GIPL with two β-Galf residues in
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In order to catalyze a non-redox reaction for the conversion of Galp to Galf, UGM
requires the flavin cofactor to be in its reduced form (Fig. 4C). Different mechanistic studies of
prokaryotic UGM have led to propose two different mechanisms for the ring contraction of
UDP-Galp to UDP-Galf. The first one portrays a nucleophilic attack by the reduced flavin to
form a flavin-Gal adduct. This reaction can occur in a Sn1, in which the flavin covalent
intermediate is formed by the attack of N5-flavin adenine dinucleotide (N5FAD) to an
oxocarbenium galactose intermediated, or Sn2 manner, where the covalent flavin intermediate
could be formed by the direct attach of the flavin by carbon 1 in galactopyranose (C1Galp) (44).
The second proposed mechanism involves the transfer of a single electron from reduced flavin to
Gal, forming a sugar-flavin adduct (44). Molecular studies have been conducted in order to
demonstrate the importance of UGM in terms of virulence and survival in other pathogens. For
example, deletion of genes encoding UGM in M. tuberculosis have shown that this enzyme is
essential for the growth and survival of these bacteria (48), whereas in the fungi A. fumigatus,
when UGM virulence was attenuated, and the fungi became more sensitive to changes in
temperature and its cell wall became thinner (49,50). Moreover, when UGM was deleted from L.
major, bGalf was completely depleted, and the parasite expressed truncated GIPLs in its
membrane and was less virulent (51). Only very few studies have been conducted in order to
understand the structure and chemical mechanism of this enzyme, and so far, we know that
UGM catalyzes a non-redox reaction and that the flavin cofactor possess a unique role in this
catalysis. Moreover, we know through the literature that UGM is important for the virulence of
the parasite, however, up to date, there haven’t been any studies to demonstrate what is the exact
role this enzyme plays in the pathogenesis of T. cruzi, and would happened in the absence of it
(44,47,52). As previously mentioned, it is well established that this enzyme is not present in
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humans (47), thus making the elucidation of its biosynthetic pathway attractive for the
development of potential drug targets or vaccines to treat Chagas disease.

I.4 What is the current toolbox to study genetic manipulation in T. cruzi?

The available chemotherapy to treat ChD has proven to be very unsatisfactory due the its
lack of full efficacy in the chronic phase and its various severe side effects. In addition, there are
no vaccines to prevent or treat the disease. Therefore, it is imperative to use new molecular
approaches to study the biology of T. cruzi in order to develop new or better therapeutic options.
With the advent of the full genomic sequence of T. cruzi in 2005, major breakthroughs in
genome-based studies has allowed us to understand the function of molecular factors that are
essential for the pathogenesis caused by this parasite, leading to the development of new
diagnostic tools and better therapeutic options. At the same time, new molecular approaches
have been created to assess and characterize gene function in T. cruzi in its different
morphological stages and how it affects its host. Some of them include gene deletion,
overexpression, insertion of reporter genes and subcellular localization of proteins. Moreover,
reverse genetics approaches, such as the development of stable tetracycline-regulated expression
vectors or high throughout cloning systems based on Gateway technology, has greatly benefited
large-scale genome projects in trypanosomes (53-55). However, the availability of genetic and
molecular tools to study T. cruzi is still limited (56,57). As of today, the pTREX vector plasmid
has proven to be the best genetic tool available in the expression and functional analysis of T.
cruzi genes. This system is driven by a ribosomal promoter that improves gene integration,
expression and clonal selection (58). However, genetic editing in T. cruzi is still very behind in
comparison to other kinetoplastid parasites such as Trypanosoma brucei, where the RNA
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interference technique has been well established. Moreover, T. cruzi requires approximately 6-8
week to generate clone mutant epimastigotes (4 times higher than Leishmania epimastigotes and
8 times longer that T. brucei bloodstream trypomastigotes) and the rounded-shape amastigotes
require a host cell to proliferate. In addition, laboratory accidents with virulent strains makes
very challenging the construction of molecular models in T. cruzi (56,57,59).

I.5 CRISPR/Cas9: an adaptive and sophisticated immune system for bacteria and archaea

In recent years, the field of genomic editing has been revolutionized by the emergence of
a novel technique called CRISPR/Cas9 (Clustered regularly interspaced short palindromic
repeats)/(CRIPSR-associated gene 9), and RNA-guided system that has been applied all around
the world in the genetic manipulation of all type of organisms, such as yeast, mammalian cells
and protozoan parasites (60,61). Initially discovered more than 20 years ago, the CRISPR system
was first described in E. coli when a group of scientists found an array of short repetitive
sequences interspaced with non-repetitive sequences (62). Later on, they observed that these
repetitive arrays were found in numerous bacteria and archaea and the spacers were identical to
mobile genetic elements (bacteriophage DNA, plasmids, etc.). Alongside, they also found that
these arrays were often associated with a set of Cas genes, encoding for potential helicases,
nucleases and various RNA-binding proteins based on sequence similarity(61,63). Over the
years, investigators concluded that these CRISPR systems are indeed adaptive defense systems
that protect bacteria and archaea from invading viruses and plasmids. The CRISPR/Cas defense
system is mediated via a three-step process: acquisition/adaptation, expression and interference.
The acquisition step begins when viral DNA gets into the cell and the foreign DNA is detected.
Here, the CRISPR system allows for integration of these short pieces of DNA in the CRISPR
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locus by employing several of these Cas proteins. Subsequently the CRISPR sequences are
transcribed into short pieces of CRISPR RNA (crRNA). These are then used with proteins
encoded by these Cas genes and work together by forming interfering complexes. They employ
information from RNA to base pair with the matching sequence in viral DNA and cut it (64-66).
Overall, there are three types of CRISPR/Cas systems, from which type I and III present similar
features, such as a large complex of specialized Cas proteins for crRNA guiding and recognition.
In contrast, type II system relies on a single Cas protein, Cas9, for RNA-guided DNA
recognition and cleavage of foreign DNA (61,67) (Fig. 6). However, a recent study conducted in
2011 by Makarova et al., which involved extensive analysis of genomic data, demonstrated
evidence for two new putative types in the CRISPR/Cas system, type IV and type V (68). With
this process, bacteria and archaea are allowed to eliminate foreign DNA elements in a memorybased system.
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Figure 6. Biology of CRISPR/Cas system as a defense mechanism for invading foreign
elements. CRISPR/Cas mediated immunity is divided in three phases: (1) acquisition; (2)
expression (CRISPR RNA biogenesis); and (3) interference. Upon infection, foreign DNA is
integrated into the CRISPR locus as a new spacer “interspaced” with identical repeats. Then, the
spacer elements are transcribed and matured into CRISPR RNAs (crRNAs), which will pair with
complementary protospacer sequences from invading genetic elements. Each crRNA functions in
complex with a Cas9 that will direct recognition and destruction of the target element. Figure
taken from (69).
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I.6 The CRISPR/Cas9 type II system as a genome editing tool for T. cruzi

The CRISPR/Cas9 type II system was adapted for genome engineering from
Streptococcus pyogenes and has been remodeled in different human pathogens such as
Toxoplasma gondii, Plasmodium falciparum, Leishmania spp., Cryptosporidium parvum, and T.
cruzi (60). Out of the three systems, this is the simplest one, as it only requires two main
components, a Cas9 endonuclease and crRNA chimera, known as guide RNA, that uses RNA for
target site recognition (61). This duplex, called single-guide RNA (sgRNA), is formed by the
fusion of a crRNA that pairs with complementary sequences of target DNA, and a transactivating crRNA (tracrRNA) which facilitates the maturation and processing of the crRNA.
This sgRNA consists 20 nucleotides (nt) that will direct the Cas 9 to the specific target sequence
using RNA-DNA base-pairing complementary rules. The sgRNA pairs with the DNA target
(known as protospacer) upstream of a protospacer-adjacent motif (PAM), with the canonical
form of 5’ NGG (where N is any nt, and G is guanine), thus directing Cas9 to target site and
produce double strand breaks (DSB) (66,70). Cas9-induced DSB can be repaired by NHEJ (nonhomologous end joining), which is error prone and leaves scars in the form of
insertion/deletion(indel) mutations, HDR (homology directed repair), which occurs in the
presence of a donor DNA, and the DSB is repaired through homologous recombination or
MMEJ (microhomology-mediated end joining), in which microhomology regions aligned on
either side of the strand break, are aligned together, causing deletion of genes between these two
homology sites (Fig. 7). It is important to highlight that even though other molecular tools, such
as ZFN and TALENS, exist to produce DSB, they rely on protein-based DNA recognition, which
requires a lot of protein engineering. In contrast, CRISPR/Cas9 relies on simple base-pair rules
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between RNA and the target DNA, and the system can be easily modified by changing to change
its target by simply editing a protospacer in the gRNA (61,66,67,71).

Figure 7. Schematic representation of the CRISPR/Cas9 complex. The RNA-guided
endonuclease Cas9 from S. pyogenes is directed towards the target DNA leading by a sgRNA
(red), which consists of 20 nt complementary to the target sequence (protospacer). In order to
cleave the target sequence, Cas9 is required to recognize a PAM sequence of 5’NGG’3 (orange)
that is located downstream of the target sequence in the genomic DNA. Upon DNA cleavage, the
DSB can be repaired by three mechanisms: (1) NHEJ, which leads to indel (insertions or
deletions) mutations on the DNA; (2) HDR, which requires the presence of a donor DNA with
homologous recombination sites flanking the region where the cleavage was done; and (3)
MMEJ, in which short homologous sequences are aligned on either side of the break to repair the
DSB. This results in deletions flanking sequences from the original break. Figure taken from
(60).
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The first study using the CRISPR/Cas9 system as a genome editing tool for T. cruzi was
reported by Peng et al. (2014) demonstrated a rapid and efficient tool to knockout multiple
endogenous genes. Here, they generated mutant cell lines that constitutively expressed Cas9 and
delivered a sgRNA by electroporation without donor DNA, demonstrating by genomesequencing that T. cruzi DNA repair, in the absence of a donor DNA, can be carried out by
microhomology-mediated end joining (MMEJ). More importantly, their work demonstrated that
the CRISPR/Cas9 system can be used to knockout multiple genes in a large gene family of genes
( b-galactofuranosyl glycosyltransferase (b-GalGT) family of 65 annotated genes), therefore
opening the door to use CRISPR/Cas-mediated knockout libraries in conserved gene families
(72).
A year later, another research group led by Dr. Roberto Docampo at the University of
Georgia-Athens, reported the usage of CRISPR/ Cas9 system to disrupt the endogenous genes
paraflagellar rod protein 1 (PFR1), paraflagellar rod protein 2 (PFR2) and GP72, a glycoprotein
localized between the flagellum and the cell body. PFR1 and PFR2 are core components of the
parasite’s flagellum. Herein, the silenced these genes by using pTREX vectors containing Cas9
and sgRNA together or separately, or a vector containing sgRNA and Cas9 plus a donor DNA
(to repair DSB by homologous recombination). Results showed successful genome silencing of
PFR2, PFR2 and GP72 with undetectable toxicity of Cas9 (56). Right after this, they were able
to use their established CRISPR/ Cas 9 system to endogenously tag T. cruzi proteins (73). In
summary, achievement of genome editing in T. cruzi using CRISPR/Cas9 has greatly improved
our understating and manipulation at the level of DNA in this parasite, leading to new strategies
that could potentially lead to development of a vaccine or new chemotherapeutic treatment.
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Chapter II: CRISPR/Cas9-mediated genetic disruption of UDPGalactopyranose mutase in T. cruzi

The complex surface coat of T. cruzi is composed of GPI-anchored glycoconjugates
which are highly associated to the virulence, survival and infectivity of the parasite. These
glycoconjugates include the GPI-mucins, trans-sialidases (TSs), mucin-associated surface
proteins (MASPs) and glycoinositolphospholipids (GIPLs). They most abundant glycoconjugates
in the T. cruzi are the heavily glycosylated mucin-like molecules and the phospholipids GIPLs. It
is known from previous studies, that GIPLs are more abundant in the epimastigote form of the
parasite, whereas GPI-mucins are more abundant in the infective form the parasite, which is the
trypomastigote form. The sugar bGalf is present in both glycoconjugates and could be a
virulence factor for the parasite, like in L. major (51). More importantly, bGalf is not present in
humans, therefore is considered an ideal drug target (25,31,42).
The main objective of our project is to eliminate UGM, the sole enzyme responsible for
the synthesis of bGalf, from T. cruzi, using the CRISPR/Cas9 approach and identify its
essentiality for the parasite. To this end, we will use epimastigote of the Dm28c strain as it has
been demonstrated that this sugar is present in this strain (42).
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II.1 Hypothesis

We hypothesize that UGM is not essential for the survival of T. cruzi, but it be might
important for the virulence of T. cruzi.

II.2 Specific aim

To knockout UDP-galactopyranose mutase (UGM) in T. cruzi using the CRISPR-Cas9
system.
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II.3 Materials and Methods

II.3.1. Trypanosoma cruzi epimastigote culture

T. cruzi epimastigotes (Dm28c clone) were grown in liver infusion tryptose (LIT)
medium supplemented with 10% heat inactivated fetal bovine serum (iFBS) at 27°C (74).
CRISPR mutant cell lines were maintained in medium containing 200 µg/ml blasticidin and/or
250 µg/ml neomycin. Growth of epimastigotes will be determined by measuring a change in
optical density from the starting concentration. A kill dose assay was conducted in order to
determine the minimum inhibitory concentration (MIC) for the antibiotics used for selection,
blasticidin (bsd) and neomycin (neo). Previously, the MIC for neomycin had been found to be
250 µg/mL (56). The MIC for blasticidin, in the presence of neomycin was determined by
measuring parasite viability over time by varying the concentration of blasticidin, namely from
350-50 µg/mL. We determined the amount of parasite by counting cells in a Cellometer X2
(Nexcelom Bioscience) counting chamber for 15 days. Results were graphed using GraphPad
Prism 6.

II.3.2. Generation of Molecular Constructs

The genomic DNA sequences of the targeted gene UGM (TriTrypDB accession number
TCDM_02308;
PFR2(TriTrypDB

http://tritrypdb.org/tritrypdb/app/record/gene/TCDM_02308)
accession

number

and

TcCLB.511215.119);

http://tritrypdb.org/tritrypdb/app/record/gene/TcCLB.511215.119). were obtained from the
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TriTrypDB database. Since PFR2 has been previously knocked out by this system, we decided to
employ it as a positive control. All the molecular constructs were kindly provided by Dr. Roberto
Docampo (University of Athens- Georgia)Protospacer and small-guide RNAs (sgRNA) specific
for UGM and PFR2 were designed and PCR amplified following the protocol established by the
Docampo lab (56).The detailed protocol is available at http://www.bio-protocol.org/e2299. In
short, the protospacer is a small sequence (~20 nt) that dictates where the gene will be cut. Here,
we decided to cut in the first 100-200 bp from the start site. In order to very that the selected
protospacer did not generate off-targeting cut sites on the genome, we employed the Eukaryotic
Pathogen CRISPR guide RNA/DNA Design Tool (http://grna.ctegd.uga.edu/) (75) and the
software ProtoMatch v1(56). sgRNAs for UGM and PFR2 were amplified by PCR with their
specific forward primers and a common reverse primer and cloned into pUC_sgRNA (vector)
(Table 1). These PCR products were subsequently cloned into the pCR2.1-TOPO vector
(Invitrogen Life Technologies) and several clones sent for sequencing with universal primers for
the T7 promoter to confirm the sequence as well as its orientation. Following, the protospacers
were cut out from the pCR2.1-TOPO vectors and cloned into the Cas9/pTREX-n vector
(Addgene) by using the BamHI site. Transformations were performed using the E. coli DH5α
strain (New England Biolabs) and clones selected with neomycin. Recombinant clones were
picked and analyzed by PCR and subsequently sequenced to confirm the orientation of the insert.
These

clones

will

correspond

to

the

constructs

pTREX/sgRNA/Cas9/UGM

and

pTREX/sgRNA/Cas9/PFR2 (56). Positive clones were isolated to obtain 100 µg of plasmid DNA
by Maxiprep (Qiagen) to perform at least 3 transfections. Following the Maxiprep procedure,
plasmid DNA was precipitated by adding 2.5 volumes of 100% ethanol (EtOH) and 0.1 vol. of 3
M sodium acetate pH 5.2. The mixture was stored at -20˚C overnight (ON). The sample was then
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centrifuged at 16,000 g in a microcentrifuge (Model 5415R, Eppendorf) for 12 min, at 4oC, and
the pellet carefully resuspended in 70% EtOH. Again, the mixture was centrifuged at max. speed
for 3 min, and the pellet air-dried. The dried pellet was resuspended in 20 µL nuclease-free water
(73).
Table 1. Primers used to generate CRISPR/Cas9 constructs.
Primer
sgRNA-PFR2 Fw
sgRNA-UGM Fw

Sequence
5’GATCGGATCCGGCACCGCCGGCTGCTGCTGGTCCGGTT
TTAGAGCTAGAAATAGC3’
GATCGGATCCGAGTGTAACGACACCCCAGGGTTTTAGAG
CTAGAA ATAGC

Common Reverse Primer

5’-CAGTGGATCCAAAAAAGCACCGACTCGGTG-3’.

II.3.3. Amplification of donor DNA template (Blasticidin-S deaminase cassette) used for
homologous recombination repair

Ultramers for UGM and PFR2 were designed to amplify a DNA cassette that will induce
DNA repair by homologous recombination containing a selectable marker blasticidin-S
deaminase (Bsd) using the pCRr2.1 TOPO vector (kindly provided by Docampo’s lab at UGA)
as a template (56) for homologous recombination. The PCR protocol was modified from Lander
et al., 2015 (56) where 50 µL final volume were used containing 25 µL GoTaq® Green Master
Mix 2X (Promega), 1µL ultramer PFR2-BSD-Fw and 1µL ultramers PFR2-BSD-Rv (Table 2),
1 µL Template DNA (TOPO/Bsd/PFR2) and 22 µL nuclease-free water. Thermocycler
conditions begin with an initial denaturation of 98° for 30 sec, followed by 35 cycles of 98°C for
15 sec, 45°C for 30 sec, and 72°C for 30 sec. A final extension was carried at 72°C for 5 min. In
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order to amplify the donor DNA for UGM, we used 0.5 µL Phusion® DNA Polymerase (NEB),
10 µL GC Buffer, 1 µL 10mM dNTPs, 1 µL template DNA, 2.5 µL reverse ultramer and 2.5 µL
forward ultramer (Table 2), and 1.5 µL sterile DMSO. The reaction was completed to final
volume of 50 µL nuclease free water. Several PCR reactions (1000µL) were performed to obtain
50 µg of donor DNA. The amplified sequence (599 bp) was analyzed by gel electrophoresis in a
2% agarose gel stained with 1µL ethidium bromide (56) PCR Products were purified using a
PCR purification kit from Qiagen (Valencia, CA). Thereafter, DNA concentration was measured,
and the donor DNA was precipitated by adding 2.5 volumes of 100% ethanol (EtOH) and 0.1
vol. of 3M sodium acetate pH 5.2. The mixture was stored at -20˚C overnight (ON). The donor
DNA was then centrifuged at 16,000 g, at 4oC, in a microcentrifuge (Model 5415R, Eppendorf)
for 12 min, and the pellet carefully resuspended in 70% EtOH. Again, the mixture was
centrifuged at max. speed for 3 min, and the pellet air-dried. The dried pellet was resuspended in
20 µL nuclease-free water (73).

Table 2. Primers to amplify donor DNA used to repair DSB in PFR2 and UGM.
Primer

Sequence

PFR2-BSD-Fw (ultramer)

5’CCTTTACACAGACTCTACAAAGATACCAAATCTCACACCAGG
AAAAAAAAAAGGAAATAACAACAAAAAACAAACAAGGAAAC
AAACAACCAAACA AGCAATGGCCAAGCCTTTGTCTCA-3’
5’CGTCTCGCTCCAGTCCGACACGTGCAGGTCCTGGATGAACTC
CTCGTTCGACAGGCAGGAGGTCTTCAGCTTCAGGTTGTGGATC
TTCTGCTTGCGCGCATTAGCCCTCCCACACATAAC-3’
5’CATACTCTTGGCGGGCAACACCGACAGCAAAGCACGACCAC
AAATCCTTAACCTCCGGCAATAACACTGAGGAACATCTATAAA
AATATTTTTATTACTAATGGCCAAGCCTTTGTCTCA-3’
5’CACCCACCGCCCCCGCACCCAAACCCACGATTCTCGCTGCAG
CACGTTCCAACCCTGCACTGCCCAATCCATCACATCATCAAAG
TATTGATAATGCGAATTAGCCCTCCCACACATAAC-3’

PFR2-BSD-Rv (ultramer)

UGM-Bsd-Fw (ultramer)

UGM-Bsd-Rv (ultramer)

25

II.3.4 Parasite transfections and selection

T. cruzi Dm28c clone epimastigotes (4 X 107 cells, at room temperature [RT], suspended
in phosphate-buffered saline [PBS], pH 7.4) were transfected in ice-cold CytoMix (25 mM
HEPES, 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 2 mM EGTA, 5 mM MgCl2, 0.5%
glucose, 100 µg/ml bovine serum albumin [BSA], 1 mM hypoxanthine [pH 7.6]) containing 50
µg of each plasmid construct (pTREX-n/Cas9/sgRNA UGM, pTREX-n/Cas9/sgRNA PFR2) and
donor DNA in 4-mm electroporation cuvettes with three pulses (1500 V, 25 µF) delivered by a
Gene Pulser II (Bio-Rad). In addition, the following controls were included: pTREX-n/Cas9,
pTREX-n/Cas9/sgscramble RNA, WT epimastigotes transfected with water, and WT
epimastigotes electroporated alone. Each transfection was performed in triplicates. After the
electroporation, each cuvette was placed at room temperature (RT) for 15 min. Thereafter, the
parasites were electroporated parasites were transferred to a flask containing 5mL of LIT media
supplemented with 20% iFBS and incubated at 27°C. After 24 h, antibiotics for selection were
added. For mutant parasites that were co-transfected with the pTREX-n/Cas9/sgRNA vector and
donor DNA (blasticidin cassette), their double-resistant selection was maintained in medium
containing 250 µg/ml Neomycin (Thermo Fisher Scientific) and 200 µg/ml Blasticidin (Gibco)
until stable cell lines were obtained. The controls were maintained in medium containing only
250 µg/ml Neomycin. For a period of 7 weeks, media supplemented with 20% iFBS and fresh
antibiotics were replaced every week.

II.3.5. Analysis of mutant parasites
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After 7 weeks of the transfections, gDNA from mutant parasites maintained under drug
selection was extracted. Briefly, 1 mL of parasite culture was centrifuged for 10 min at 800 g, at
4oC. Thereafter, the parasite pellet was resuspended in 150µL of TELT (50 mM Tris pH 8, 62.5
mM EDTA pH 8, 2.5 M LiCl, 4% Trion X-100) buffer by inverting the tube three times and then
incubated for 5 min at RT. Then, 150µL of Phenol: Chloroform: Isoamyl Alcohol (25:24:1, v/v)
(Thermo Fischer Scientific) was added and incubated for 5 min in a shaking rocker. The mixture
was centrifuged at 16,000 g, for 5 min at 4°C and the aqueous phase was collected. The gDNA
was precipitated following the protocol described by Lander et al., (2016) (73). Disruption of T.
cruzi UGM and PFR2 (positive control) was verified by PCR analysis with primers (Table 3)
annealing outside the homologous regions of the donor DNA (Bsd cassette). For both genes we
used the Phusion High-Fidelity DNA Polymerase (New England Biolabs). A 50 µL final volume
were used containing 0.5 µL of Phusion DNA Polymerase, 10 µL 5X Phusion HF buffer, 1 µL
dNTPs (10mM), 1 µL forward primer, 1 µL reverse primer, 1 µL DMSO and 1 µL gDNA
(100ng/ µL). Thermocycler conditions begin with an initial denaturation of 98° for 30 sec,
followed by 35 cycles of 98°C for 10 sec, 60°C for 30 sec, and 72°C for 20 sec. A final extension
was carried at 72°C for 10 min. The amplified sequence for UGM-KO, PFR2-KO and respective
controls were analyzed by gel electrophoresis in a 2% agarose gel stained with 1µL ethidium
bromide.
Table 3. Primers used to verify integration of donor DNA in PFR2 and UGM.
Primer
PFR2-Fw-disruption
verification
PFR2-Rv-disruption
verification
UGM-Fw-disruption

Sequence
5’-CACATAATACTCATTCATGCAAAAC-3’
5’-AAGTTCTTGCGCCTTCTCGT-3’
5’-CTCATAGCTGGTCTTGCAAC-3’
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verification
UGM-Rv-disruption
verification

5’-GTTCCGGCAAACGATGAA-3’

II.3.5. Fluorescence microscopy

Transfected epimastigotes at a density of 1x106 cells were harvested by centrifugation at
800 g, for 10 min, at 4oC. Parasite pellet was washed with PBS, and allowed to settle in poly-Llysine coated microscope slides (Thermo Fisher Scientific) for 10 min. Then, the parasites were
fixed with 4% paraformaldehyde (Thermo Fisher Scientific) for ten minutes, washed one more
time with PBS and mounted with anti-fade mounting medium with DAPI (4',6-diamidino-2phenylindole, dihydrochloride, Vector Laboratories, Inc.) (76). Microscope slides were observed
with a (Zeiss LSM 700 Laser Scanning Microscope).
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Chapter III: Results

III.1 Molecular constructs of CRISPR/Cas9 in T. cruzi
The sequences of UGM and PFR2 were obtained from the TriTrypDB database. Once the
protospacers and sgRNAs were designed, they were cloned into the pTREX-n vector. The
pTREX-n vector contains the Cas9-HA-2XNLS-GFP fusion gene, which consists of the S.
pyogenes Cas9 sequence with a simian virus (SV40) nuclear localization signal (2XNLS)
repeated twice and a GFP (green fluorescence protein) marker. Here, Neomycin was added as a
selectable marker to confer resistance in mutant parasites. The sequence of our sgRNA for each
gene and Cas9 was added upstream and downstream of the HX1 trans-splicing signal in the
pTREX-n vector(56) As a result, we generated the T. cruzi PFR2 pTREX-n/Cas9/sgRNA and T.
cruzi UGM pTREX-n/Cas9/ sgRNA vectors as shown in Figure 8. The full sequence map for
pTREX-n/Cas9 can be obtained from Addgene plasmid (https://www.addgene.org/68708/).
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Figure 8. Restriction map used in the CRISPR/Cas9 system for genome editing of UGM
and PFR2 in T. cruzi. Cas9/pTREX-n (56), comes from an S. pyogenes Cas9 sequence with a
twice-repeated sequence of the simian virus 40 nuclear localization signal and a GFP in the
pTREX-n backbone. The specific sgRNA fragment of each gene was inserted through the
BamHI site. This plasmid confers resistance to the antibiotic neomycin (Neo). Transfection with
this vector will produce green fluorescent parasites. Figure taken from Lander et al., 2015 (56).
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III.2 T. cruzi epimastigote kill dose assay

T. cruzi epimastigotes (Dm28c clone) were grown at 28⁰C in liver infusion tryptose (LIT)
medium supplemented with 10% FBS (74). A kill dose assay was performed in order to obtain
the MIC for the 2 antibiotics used for selection, neomycin and blasticidin. For two weeks,
epimastigotes were grown at different concentrations of Bsd (350-50 µg/mL) and Neo (250
µg/mL). Every day, we determinate the number of parasites by counting them in a Cellometer
chamber. As observed in Figure 9, the different concentrations of Bsd with Neo killed the same
number of parasites, in comparison to the negative control.

Figure 9. Kill dose curve of wild-type T. cruzi epimastigotes (Dm28c), with different
concentrations of Bsd and 250 µg neomycin (Neo). Red line represents epimastigotes without
exposure to antibiotic.
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III.3 Amplification of donor DNA (BSD cassette) to repair double strand break made by
Cas 9

Ultramers were designed to amplify a donor DNA cassette that will repair the DSB by
homology recombination. The donor DNA amplified 100bp upstream and 100bp downstream of
the Cas9 cutting site plus 399bp of the marker Blasticidin used for antibiotic resistance. Multiple
PCR reactions using the Promega GoTaq® Green Master Mix and the Phusion® High-Fidelity
DNA Polymerase (New England Biolabs) were used to amplify the donor DNA of PFR2 and
UGM, respectively. Thereafter, the amplification of donor DNA for UGM and PFR2 were
analyzed in a 1% agarose gel, showing a band corresponding of 599 bp corresponding to the
donor DNA of each gene (Figure 10). Subsequently, the PCR reactions were purified and
precipitated with ethanol to obtain 50 µg of donor DNA necessary for transfection.
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Figure 10. 1%-Agarose gel showing amplification of donor DNA used to repair DSB from
UGM (A) and PFR2 (B). Donor DNA is shown as a PCR product of 599 bp. (A) UGM/Bsd:
lane 1, Gene Ruler DNA Ladder Mix (Thermo Fischer Scientific Inc.); lane 2, water control; lane
3, PCR product. (B) PFR2/Bsd: lane 1, Gene Ruler DNA Ladder Mix (Thermo Fischer Scientific
Inc.); lane 2, water control; lane 3, blank (no sample); lane 4, PCR product.
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III.4 Fluorescence microscopy of T. cruzi UGM-KO and PFR2-KO mutant parasites
In our study, we used a positive control T. cruzi PFR2, because its genome editing
produce visible changes in its phenotype, as it is an important component of the paraflagellar rod
in the parasite. As observed in Figure 11A, B, the parasites present a certain level of flagellar
detachment. In UGM-KO epimastigotes, confocal microscopy revealed that GFP fusion proteins
was relocated mostly at the posterior site of the parasite (Figure 11C), therefore demonstrating
the integration of the pTREX-n/Cas9/sgRNA vector.
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Figure 11. Fluorescence microscopy of PFR2 and UGM T. cruzi mutant parasites
controlled under the expression of CRISPR/Cas9. (A) Live images of PFR2-KO mutant
parasites presenting partial flagellar detachment (arrows). (B) Single PFR2-ablated epimastigote
showing detached flagella (arrow). (C) UGM-KO epimastigotes with green fluorescent protein
co-localized with DAPI-stained nuclei (blue).
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III.5 Generation of T. cruzi UGM mutants by CRISPR/Cas9-induced homologous
recombination with a selectable marker

In order to repair the double strand break caused by Cas9, we decided to transfect a donor
DNA fragment, which consists of a linear cassette with blasticidin flanked by homology arms
100-bp upstream and 100bp-downstream of the start codon, near the Cas9 target site in UGM
and PFR2. After co-transfection of pTREX-n/Cas9/sgRNA and donor DNA, mutant cell lines
were maintained under double antibiotic selection (neomycin and blasticidin). 8 weeks after,
double-resistant cell lines were subjected to PCR analysis. Disruption of UGM was verified
using primers that annealed outside the homology regions on the blasticidin cassette, to amplify a
fragment from nt -127bp to nt +334bp (Figure 12A). A fragment of 666bp corresponded to T.
cruzi-KO parasites in which the DSB was repaired by homologous recombination, therefore
demonstrating DNA disruption. The original fragment, corresponding to WT epimastigotes,
represents a fragment of 461bp (Figure 12C). Similarly, for our positive control PFR2,
previously knocked out by Lander et al., (2015) (56), we used primer annealing outside the
homology region of the Bsd cassette to amplify a fragment -142 bp to +234 bp on the PFR2
locus (Figure 12B), therefore amplifying a fragment of 696bp in the T. cruzi/PFR2-ablated
parasites and 376bp in the WT form (Figure 12C).
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Figure 12. Research strategy used to generate T. cruzi UGM and PFR2 mutant parasite by
CRISPR/Cas9-induced homologous recombination. (A) Schematic representation of the
strategy used to generate T. cruzi UGM-KO parasites using homologous recombination to repair
the DSB caused by Cas9. A blasticidin-S-deaminase cassette was inserted to repair DNA.
Primers annealing outside the homologous regions of the Bsd cassette were designed to amplify
a fragment of 461 bp in the intact locus of T. cruzi UGM, whereas in the mutant parasite, a
fragment of 666 bp was amplified after insertion of Bsd cassette. (B) Strategy used to generate T.
cruzi PFR2-ablated parasites. Primers outside the homology regions of Bsd were designed to
amplify a fragment of 376 bp in WT parasites and 696 bp in mutant parasites. (C) PCR products
were obtained from a 1%-agarose gel. Lanes from left to right: 1, UGM WT; 2, UGM pTREXn/Cas9/sgscramble RNA (negative control); 3, UGM pTREX-n/Cas9 (negative control); 4,
UGM-KO; 5, water control (negative control); 6, PFR2-KO (positive control); 7, PFR2-WT.

37

Chapter IV: Discussion and future studies
Chagas disease affects approximately 6-8 million people in Latin America, where the
disease is mainly endemic. However, recent trends in migration have spread the disease to other
countries around the world, such as the U.S, Australia, Japan and Spain, raising an alarm month
the public health community. This menacing become important due to its economic burden.
Cardiac and digestive complications in the chronic phase of ChD results in an increase of health
and treatment cost. Since the majority of the people affected by this disease lives in poor
conditions, treatment is often unreachable leading to a high mortality (10). In addition to this,
current treatment is highly toxic and partially effective during chronic phase, and there is still no
vaccine for ChD. For this reason, it is imperative to study and elucidate the virulence factors of
T. cruzi and their mechanism of infection, to develop chemotherapeutic drugs for the treatment
of ChD (18).
For the last 20 years, T. cruzi has been extensively manipulated at the genetic lever in
order to better understand its biology. Some of the tools currently available to perform molecular
manipulation in T. cruzi include integration of expression vectors pRIBOTEX and its derivate
pTREX, in which both contain a neomycin selectable marker that is expressed under the Pol I
rRNA promoters (58,77). In addition, these expression vectors have been modified by addition of
fluorescent protein sequence, such as GFP (green fluorescent protein) and RFP (red fluorescent
protein) as a way to monitor parasite infection, through subcellular localization of fused proteins.
However, we’re still facing limitations in the genetic manipulation of T. cruzi (78). Over the past
three years, several groups have reported the implementation of the CRISPR/Cas9 systems as a
genome editing tool in different parasites such as P. falciparum and Toxoplasma gondii. In 2015,
two separate studies conducted first by Peng et al. (2015), and subsequently Lander and
colleagues (2015), demonstrated that CRISPR/Cas9 can be used as an effective way to disrupt
genes in T. cruzi genome.
Following the ideas established by Lander et al. (2015), here we report the usage of
CRISPR/Cas9 system in order to knockout the genes UGM and PFR2, the first potentially
involved in the virulence of T. cruzi (42) and the second one, in the flagellar development and
motility (56). We believe that UGM is not essential for the survival of T. cruzi, therefore removal
of this gene will not kill the parasites. Here, we introduced the plasmid pTREX-n/Cas9/sgRNA,
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along with a blasticidin cassette for homologous recombination into T. cruzi (Dm28c)
epimastigotes. We chose PFR2 as our positive control, because it was previously demonstrated
that disruption of this gene bears flagellar disruption without killing the parasite, as it is
appreciated in Fig. 11B, therefore making it easy to trace the phenotypic changes caused by
Cas9. After 7 weeks of transfection, we PCR mutant parasites both UGM and PFR2, in order to
detect insertion of BSD in the site where Cas9 made the doubles strand break (DSB). The first
thing we noticed is that UGM-KO parasites did survive after transfection, therefore
demonstrating that indeed this gene is not essential for the survival of T. cruzi. We designed a
strategy were primers annealing outside the homologous regions of the DSB amplified a
fragment of 461 bp in WT UGM epis and 376 bp in WT PFR2 epis, whereas as mutant parasites
displayed a fragment of 666 bp in UGM-KO and 696 bp in PFR2-KO epimastigotes. As it is
appreciated in Fig. 12, both KO-genes present two bands correspond to the WT and KO
fragment, therefore suggesting that what we have right now is a mixed population in which some
parasites were able to take up the pTREX-n plasmid but not the donor DNA, whereas in other
parasites both the plasmid and donor DNA were integrated successfully. What is interesting, is
that we should have seen complete disruption of PFR2 as it was previously demonstrated by
Lander et al. (2015). In their study, the recovery time after transfection was shorter (5 weeks)
and T. cruzi PFR2 was completely absent in transfected parasites (56). However, it is important
to notice that even though two fragments are amplified in mutant parasites, PFR2-KO shows the
fragment corresponding to the WT with less intensity in comparison to the 696-bp fragment;
therefore, we believe that WT parasites in the mixed population is less in comparison with the
mutant population.
In order to overcome this issue, we will separate these mixed populations for single-cell
cloning isolation. Here, we will seed mutant parasites up to a density of 1 parasite/well in
conditional media supplemented with different concentrations of blasticidin (250 µg/mL-500
µg/mL) until we can isolate individual clones. As a second strategy, we will cultivate the
parasites in semisolid media supplemented with male human urine. A previous study conducted
by Fajardo and colleagues (2016), demonstrated that semisolid LIT supplemented with human
urine allows for the growth and isolation of T. cruzi and T. brucei strains from mixed populations
cultures in a period of 20 to 30 days approximately (79). From what we have seen from other
studies, isolation and manipulation of T. cruzi clones requires the usage of limiting dilutions in
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order to isolate clonal populations. However, one of the major challenges is that this is timeconsuming and the period time to obtain colonies can range up to 30 days or more (76,80). It is
possible that the molecular machinery of T. cruzi requires more to cause genomic mutations
before DNA replication (72).
In summary, our study describes the usage and implementation of the CRISPR/Cas9
machinery as a genome editing tool T. cruzi. Here, we were able to generate a plasmid with the
2 main components of CRISPR, the nuclease enzyme Cas9 fused with a GFP marker and our
sgRNA. In addition, we were able to introduce antibiotic resistance markers, which overall all of
this was able to produce the desired mutations in our parasites. The results and current work of
this study represent the efficiency of the CRISPR/Cas9 system as a new tool that can be used to
analyze gene function in T. cruzi. With this in mind, we hope that this contribution can lead to
facilitate genomic studies in the parasite.
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